The goal of the Clinical Discovery group
is to develop new RNA technologies for disease diagnosis and treatment.
In recent years several successful RNA therapies have been introduced to the market. An exceptional feature of RNA therapeutics is their ability to target any RNA vis complementary sequence, enabling therapies for many diseases. We
believe RNA therapies will become increasingly common mainstream clinical
tools in the relatively short-term future.
RNAs are often very
informative readouts of disease status: the presence or absence of particular
RNAs and isoforms can be specific to particular pathologic conditions (e.g.,
infection, cancer, and ischemia) and therefore have value. However, because the
transcriptomes of normal and diseased cell types are complex and often poorly
characterized, the potential utility of RNAs as biomarkers has not been fully
The Denver/Boulder area is a major hub of RNA
biotechnology and we will form new
partnerships with companies. For example, miRagen is a
clinical stage biopharmaceutical company that develops RNA-targeting therapies
with a specific focus on microRNAs and diseases of high unmet medical need.
A goal of the RNA Bioscience Initiative is to
provide a fluid pipeline from basic research to development of RNA-based therapeutics and
diagnostics at the Anschutz Medical Campus.
Additional faculty will be recruited to enhance this research area.
Dr. Craig Jordan heads the RNA Clinical Discovery group.